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Over the last decade, the concept and
nomenclature of microglial phenotype
polarization has been carried over from the
peripheral macrophage literature. How-
ever, it is not entirely correct to view these
two cell types as overlapping. Microglia,
although related to macrophages, have
several differences and their own unique
repertoire of features. In particular,
microglia arise from a distinct early yolk
sac progenitor population and therefore
have different developmental origins than
macrophages (1). Furthermore, once in the
central nervous system (CNS), microglia
are maintained through local self-renewal
(2). Under normal conditions, there is no
infiltration of peripheral macrophages (3).
Microglia also maintain expression profiles
distinct from peripheral macrophages (4).
This demonstrates that microglia are not
simply macrophages that have migrated
into the brain; rather, they are a distinct
cell type.
These ideas have led to a reassess-
ment of microglia activity, leading many
researchers to shift their thinking on
glial biology in general. One of the
more outdated concepts carried over from
macrophages is the idea that microglia
in the healthy brain exist in a “rest-
ing” state. Through a variety of stimuli
these “resting” cells can rapidly be “acti-
vated,” yielding microglia that are cyto-
toxic (5). These “activated” microglia were
described in and were thought to play a
major driving role in many neurodegener-
ative diseases (6). Thus, microglia “activa-
tion” took on a largely negative connota-
tion. Taking cues from ongoing work in
peripheral macrophages, this initial con-
cept of microglia “activation” being gen-
erally harmful gave way to more specific
ideas suggesting there was not just one
kind of “activation.” Under the influence of
either pro- or anti-inflammatory cytokines,
microglia could be polarized into an
inflammatory or anti-inflammatory phe-
notype, designated classically and alterna-
tively activated microglia, respectively (7).
Others have given different designations
not solely based on inflammation but from
inhibiting vs. healing functions, and label
them M1 and M2, respectively (8). It is
now becoming clear that the responses of
microglia, like macrophages, are heteroge-
neous: these responses can include pro-
and anti-inflammatory signatures within
single cells and small, nearby popula-
tions and are driven by the local environ-
ment that can supply M1 and M2 polar-
izing cues simultaneously (9). Therefore,
microglial responses are much richer than
the dichotomous nomenclature suggests. It
is common to represent microglia polar-
ization as a spectrum with each respec-
tive phenotype occupying the extremes
of the scale (10). However, it is unclear
whether the diverse functional responses
observed are a product of many different
kinds of microglia subsets or simply vary-
ing ratios of M1 and M2 microglia. While
there is much work that details this spec-
trum of activation, and much remains to be
investigated, an interesting but overlooked
area is the phenotype of the “resting”
microglial cell.
Classically, those who study microglial
function in a healthy, normal brain are not
the same groups that study microglia in an
“activated” or disease setting. However, it
appears that the microglia in each of these
settings may be more similar than origi-
nally thought. The notion that microglia
are truly “resting” has long been cast aside.
The advent of in vivo techniques, in par-
ticular 2-photon microscopy, has revealed
the constant surveillance and activity of
microglia, even in the absence of tradi-
tional activation signals (11). Therefore, it
might be incorrect to view microglia in the
normal, healthy CNS as a distinct popula-
tion that can become “activated.” Rather, it
seems likely that even at baseline, microglia
are already on the activation spectrum. So
the question arises, where on the spectrum
are they?
Inflammation in the brain is typically
associated with harmful outcomes. Even
acute, low level inflammation can impair
synaptic function, leading to cognitive
dysfunction and behavioral abnormalities
(12). Moreover, neuroinflammation has
been recognized as a pathological hallmark
in most chronic neurodegenerative diseases
(13). This demonstrates the sensitivity of
the brain to inflammation and the impor-
tance of protecting the CNS from insult.
This protective role has generally been
assigned to M2 microglia. Many investi-
gators have observed protective effects of
M2 cells; such as elevated neuronal survival
and process extension after treatment with
M2 conditioned media (14), or as reported
in numerous papers that detail the ben-
eficial effect of direct treatment with M2
inducing agents (15). However, all of these
take place during pathology and do not
consider the normal protective function of
microglia. Thus, given the critical role of
basal microglia in maintaining homeosta-
sis, an attractive hypothesis is that under
normal conditions, microglia are skewed
toward a protective, anti-inflammatory
phenotype. In fact many of the normal
functions of microglia are reminiscent of
M2 cells, although they are not as promi-
nent as fully polarized cells. Even with-
out stimulation, microglia are vital sources
of important, neurosupportive cytokines
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such as IGF-1 and BDNF (16–18). Neu-
roprotective cytokine secretion is generally
considered an M2 microglial function, but
we now know it also occurs in “resting”
microglia, albeit at lower levels. Indeed,
in models that lack proper M2 inducing
signals like IL-4−/− and SCID mice, cog-
nitive impairment is observed, which was
attributed to decreased production of these
necessary neurotrophins (19, 20).
Furthermore, microglia in a basal state
share another important function with
fully polarized M2 microglia, namely, rapid
and efficient debris clearance (21). This
process, which is one of the quintessen-
tial defining functions of M2 polarized
cells, seems to be a default function for
microglia. Although the concept of phago-
cytosis is not unique to alternatively acti-
vated microglia, the speed and quality at
which this occurs differs between the phe-
notypes. In contrast to M1 polarized cells,
where a slower and less acidic phagosome
is beneficial for downstream immune func-
tions such as antigen-presenting abilities, a
rapid, more acidic phagosome aids M2 cells
in quick, efficient removal of debris (22).
This speed and efficiency can be observed
in the highly dynamic process called synap-
tic pruning, which is characterized as rapid
elimination of developing synapses. In the
past several years, microglia have been
shown to be crucial to this process (23).
This concept is thought to be carried over
into the adult but at a less dramatic level
(24). The role of microglia in normal
synaptic maintenance is not fully under-
stood, so it is difficult to directly attribute
baseline phagocytic function to an M2
related mechanism. However, due to the
speed and efficiency at which this process
occurs, we can speculate that this type of
phagocytosis shares more similarities with
M2 than M1 polarized microglia.
In addition to the neuroprotective and
functional similarities resting microglia
share with traditionally polarized M2
microglia, skewing to an M2 state can
be seen in the receptor profile resting
microglia express. For example, unlike
macrophages, microglia express very low
levels of MHCII (25). Only when microglia
polarize to an inflammatory phenotype do
they upregulate MHCII expression (26).
Contrary to MHCII, DC-SIGN has been
observed on microglia in the normal brain.
This c-type lectin receptor, which has been
implicated in promoting immune home-
ostasis, also maintains the immunosup-
pressive environment in the healthy brain
(27). By limiting particular surface recep-
tors while expressing others, microglia
are biased toward a particular phenotype,
namely anti-inflammatory. However, it
appears that this M2 biased phenotype may
change with age. For still unknown reasons,
there is a loss of signals that keep microglia
anti-inflammatory. During normal aging,
a reduction in IL-4Rα is observed as well
as a decreased sensitivity to other anti-
inflammatory cytokines (28). This is mir-
rored by an increase in sensitivity to proin-
flammatory cytokines, suggesting a switch
in the basal phenotype of microglia (29).
A similar switch, termed priming, has been
observed after microglia were exposed to
inflammatory cytokines. Following the ini-
tial inflammatory insult, microglia appear
to return to their basal state. However,
with a second inflammatory stimulus
these “primed” microglia produce signifi-
cantly more inflammatory cytokines than
unprimed microglia (30), suggesting that
their basal state is altered toward a more
M1 phenotype. Age-associated and prim-
ing switches may be involved in increased
susceptibility to neurodegenerative disor-
ders (31).
Keeping microglia skewed toward a
non-inflamed state is critical for normal
homeostasis and specific control mecha-
nisms exist that actively prevent microglia
from adopting an inflammatory profile. In
particular, neurons express several recep-
tors and ligands that signal to their coun-
terparts specifically localized on microglia.
CX3CR1, CD200, CD47, TREM2, and sev-
eral other receptors have been identi-
fied that participate in constant cross-talk
between microglia and neurons (32). Inter-
estingly, in genetic knockout mice missing
CX3CR1, impaired cognition was observed
(33). Two explanations appear likely. First,
the loss of direct inhibition resulted in
increased inflammation, which in turn,
caused cognitive dysfunction (33). Sec-
ondly, the loss of CX3CR1 resulted in
impaired phagocytic ability (23) and sub-
sequent loss of proper synaptic pruning
during a critical developmental period,
as discussed previously. Although differ-
ent, both of these explanations share the
idea that divergence from proper nor-
mal baseline function (namely M2 skewed
functions) results in CNS pathology. Fur-
thermore, this suggests that neurons, under
normal conditions, are active in control-
ling microglial polarization. This envi-
ronmental control on phenotype skewing
poses an interesting question, is basal state
polarization present in other tissue spe-
cific macrophages? The answer is most
likely yes. However, it seems that other tis-
sue macrophage cells such as peritoneal,
lung, or splenic red pulp macrophages all
exhibit greater diversity in their normal
gene expression and most likely, basal func-
tion when compared to microglia, even
though they a share common yolk sac
progenitor (1, 34). Therefore, it is hard to
directly compare between the cell types.
This demonstrates the large role the envi-
ronment plays in skewing cells to the needs
of a specific tissue. In the CNS, an anti-
inflammatory state is most beneficial so
the environment favors slight M2 skew-
ing. It would be interesting to characterize
potential skewing in other organs and how
that relates to normal resident macrophage
function.
The idea that microglia exist as a skewed
population in normal, non-pathological
tissue highlights this phenotype as an
innate characteristic of microglia. The clas-
sical view of macrophage biology is that
the adaptive arm of the immune system,
primarily T cells, controls phenotypes via
release of cytokines such as IFN-γ or IL-
4 (35, 36). Unfortunately, it is difficult to
prove innate or adaptive control in periph-
eral tissue due to the normal presence of T
cells. However, the healthy brain is largely
devoid of T cells,which accentuates the idea
that M2 phenotype skewing is a default,
innate function of microglia (37). Interest-
ingly, similar ideas have been proposed for
macrophages (38).
In conclusion, to properly understand
and discuss microglia, we have to do
away with terms such as “activation” and
“resting.” By using these outdated con-
cepts, we fail to acknowledge the com-
plex plastic nature of microglia. In addi-
tion to not correctly representing the
non-pathological, normal functions of
microglia, the term “activation” is vague
and provides no specific information about
the many possible microglial phenotypes.
Microglia are always “active,” so the true
distinguishing feature is where they exist on
the phenotype spectrum. Healthy, normal
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brain microglia do not sit precisely in the
center between inflammatory and anti-
inflammatory cells. Rather, these sentinel
microglia are slightly shifted toward an
anti-inflammatory phenotype, which is
beneficial to brain homeostasis. The field of
microglial biology does not need to battle
over nomenclature for baseline microglia.
No single term can adequately encompass
all microglial functions at all times. But it is
important to recognize that these cells are
a plastic population that can dynamically
shift between a spectrum of phenotypes
and should not be boxed into fixed, rigid
“activation” states.
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